Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)

17. november 2026 oppdatert av: AeroRx Therapeutics Inc.

Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Studieoversikt

Detaljert beskrivelse

Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.

Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.

AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.

The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.

Studietype

Intervensjonell

Registrering (Antatt)

64

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • London, Storbritannia
        • Rekruttering
        • Parexel
      • Manchester, Storbritannia
        • Rekruttering
        • Medicines Evaluation Unit

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female aged 40 to 75 years, inclusive, at the time of informed consent

  • Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1

  • Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:

    • FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
    • FEV1/forced vital capacity (FVC) ratio < 0.70
    • ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
  • Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit

  • Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)

  • Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines

  • Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose

  • Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit

  • Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose

  • Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose

  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
  • Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
  • Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
  • Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
  • Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
  • Prior lung volume reduction surgery or history of chest/lung irradiation
  • Daily oxygen therapy for > 12 hours per day
  • Body mass index >35 kg/m2
  • Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
  • Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
  • Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
  • Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
  • Donation of 450 mL of blood within 8 weeks of Screening Visit 1
  • Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
  • History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
  • History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
  • Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
  • History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Double-blind

Eksperimentell: Aero-001 lav dose

Double-blind

Eksperimentell: Aero-001 høy dose

Double-blind

Eksperimentell: Aero-002 lav dose

Double-blind

Eksperimentell: Aero-002 høy dose

Double-blind

Eksperimentell: AERO-001 medium dose

Double-blind

Eksperimentell: AERO-002 medium dose

Double-blind

Eksperimentell: AERO-007

Double-blind

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Bronchodilation - FEV1
Tidsramme: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Bronchodilation - FEV AUC
Tidsramme: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Bronchodilation - Peak FEV1
Tidsramme: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Bronchodilation - time to onset of FEV1 >100mL
Tidsramme: Change in FEV1 >100mL from pre-dose on Days 1 and 14
Change in FEV1 >100mL from pre-dose on Days 1 and 14

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pharmacokinetics - Cmax
Tidsramme: 0-24 hours on Days 1 and 14

Cmax (maximum plasma concentration)

0-24 hours on Days 1 and 14
Pharmacokinetics - AUC
Tidsramme: AUC(0-6 hours) on Days 1 and 14

AUC (area under the plasma concentration)

AUC(0-6 hours) on Days 1 and 14
Pharmacokinetics - Tmax
Tidsramme: Tmax on Days 1 and 14

Tmax (time to maximum concentration)

Tmax on Days 1 and 14
Treatment-emergent adverse events (TEAEs)
Tidsramme: Up to approximately Day 14

Number of participants with TEAEs

Up to approximately Day 14
Blood Pressure
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in Blood Pressure

Up to approximately Day 14
Heart Rate
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in Heart Rate

Up to approximately Day 14
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in QTcF

Up to approximately Day 14
Clinical laboratory - Hematology
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in hematology parameters

Up to approximately Day 14
Clinical laboratory - Blood Chemistry
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in blood chemistry parameters

Up to approximately Day 14

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. november 2026

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. september 2027

Datoer for studieregistrering

Først innsendt

14. oktober 2026

Først innsendt som oppfylte QC-kriteriene

19. oktober 2026

Først lagt ut (Faktiske)

26. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere